CIA
DFTX

Concurrent Investment Advisors’s Definium Therapeutics DFTX Stock Holding History

Concurrent Investment Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$402K Buy
21,285
+888
+4% +$15.1K ﹤0.01% 1320
2025
Q4 		$273K Buy
+20,397
New +$252K ﹤0.01% 1461

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Concurrent Investment Advisors's DFTX Position: Q1 2026 in Review

Concurrent Investment Advisors increased its Definium Therapeutics (DFTX) stake by 4.4% in Q1 2026, buying an estimated $15.1K and bringing the position to 21,285 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #1320.

Concurrent Investment Advisors first reported a position in DFTX in Q4 2025 and has held it in 2 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Concurrent Investment Advisors held 21,285 shares of Definium Therapeutics worth $402K as of Q1 2026.
  • Concurrent Investment Advisors bought 888 Definium Therapeutics shares in Q1 2026, an estimated $15.1K.
  • Definium Therapeutics made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q1 2026, its #1320 holding.
  • Concurrent Investment Advisors first reported a position in Definium Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Concurrent Investment Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.